Analyst Rating Update on Fibrocell Science Inc (FCSC)

Fibrocell Science Inc (NASDAQ:FCSC) : 3 analysts are covering Fibrocell Science Inc (NASDAQ:FCSC) and their average rating on the stock is 1.67, which is read as a Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 1, which recommends a Strong Buy affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Fibrocell Science Inc (NASDAQ:FCSC) : The consensus price target for Fibrocell Science Inc (NASDAQ:FCSC) is $6.17 for the short term with a standard deviation of $5.35. The most optimist securities analyst among the 3 who monitor the stock believes that the stock can reach $12, however, the pessimist price target for the company is $2.

For the current week, the company shares have a recommendation consensus of Buy.

Fibrocell Science Inc (NASDAQ:FCSC): On Tuesdays trading session , Opening price of the stock was $1.38 with an intraday high of $1.39. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $1.14. However, the stock managed to close at $1.19, a loss of 13.14% for the day. On the previous day, the stock had closed at $1.37. The total traded volume of the day was 1,439,013 shares.

In an insider trading activity, Pernock David, CEO of Fibrocell Science, Inc. had purchased 3,000 shares on November 13, 2015 in a transaction. The price per share was $5 and the total amount of the disclosed transaction was $15,000.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.

Fibrocell Science, Inc. (Fibrocell) is an autologous cell therapy company focused on developing treatments for rare and serious skin and connective tissue diseases. The Companys lead orphan gene therapy program is in late-stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). In addition to its gene therapy program, the Company is pursuing the medical application of azficel-T for vocal cord scarring using its autologous fibroblast technology. The Company is also in pre-clinical development for its second gene therapy program for linear scleroderma. The Companys collaboration with Intrexon Corporation, a synthetic biology company, includes using genetically modifying autologous fibroblast cells to express collagen VII that is missing or inactive from patients with RDEB.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *